Diagnostic imaging prior to 90Y-ibritumomab tiuxetan (Zevalin) treatment in follicular non-Hodgkin's lymphoma.
Add-on treatment of follicular non-Hodgkin's lymphoma (NHL) with yttrium-90 labelled ((90)Y) ibritumomab tiuxetan (Zevalin) has become an efficacious asset in standard treatment concepts of this disease. First-line treatment with Zevalin is currently under way. Whereas in the U.S. and Switzerland a prediagnostic imaging with (111)In-ibritumomab tiuxetan is mandatory, in Europe there is no such prerequisite. It is shown in this article why a prediagnostic imaging or dosimetry is not necessary as an additional mandatory safety measure to confirm the expected biodistribution.
Otte
Andreas
A
Division of Clinical Technologies Implementation, Center of Clinical Trials,University Medical Center Freiburg Elsaesser Str. 2, Freiburg, Germany. andreas.otte@uniklinik-freiburg.de
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003952:Diagnostic Imaging / Q000379:methods*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis* / Q000532:radiotherapy*; D018579:Patient Selection; D011379:Prognosis; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan